Significant improvement in disease and depression severity at 6 weeks in adults with bipolar I and bipolar II depression1

CGI-BP-S total score was the key secondary endpoint in the monotherapy trial1,2*

In the monotherapy study, patients saw a 3.5-point reduction at Week 6 compared to 2.5-point reduction with placebo.
In the monotherapy study, patients saw a 3.5-point reduction at Week 6 compared to 2.5-point reduction with placebo.

CAPLYTA 42 mg (n=188)
Placebo (n=188)


CGI-BP-S depression score was the key secondary endpoint in the adjunctive therapy trial (with lithium or valproate)3†

In the adjunctive therapy study, patients saw a 1.8-point reduction at Week 6 compared to 1.5-point reduction with placebo.
In the adjunctive therapy study, patients saw a 1.8-point reduction at Week 6 compared to 1.5-point reduction with placebo.

CAPLYTA 42 mg (n=188)
Placebo (n=188)

These are well-established research rating tools measuring the clinician's overall clinical impression of the patient.4

*The CGI-BP-S (Clinical Global Impression-Bipolar-Severity of Illness scale) total score is a clinician-rated scale that measures the patient’s current illness state on a 21-point scale that assesses depression, mania, and overall illness, where a higher score is associated with greater illness severity. Baseline scores were 10.3 for CAPLYTA and 10.2 for placebo.1,3
The CGI-BP-S depression score is a clinician-rated scale that measures the patient’s current illness state on a 7-point scale, where a higher score is associated with greater illness severity. Baseline scores were 4.7 for CAPLYTA and 4.6 for placebo.1,3

Help LYTE THEIR WAY with the CAPLYTA Patient Brochure

References: 1. CAPLYTA prescribing information, 2022. 2. Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. Published online September 23, 2021. doi:10.1176/appi.apj.2021.20091339. 3. Data on File. 2021. 4. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgemont). 2007;4(7):28-37.